Atomic AI

Atomic AI is revolutionizing the field of drug discovery by deploying artificial intelligence to develop innovative, RNA-centric medicines. The company's cutting-edge R&D platform, which has already garnered attention by featuring on the cover of Science, focuses on addressing areas of high unmet medical need. This revolutionary platform is continuously enhanced through the creation of new machine learning methods and unique foundation models, leveraging extensive in-house experimental data.

Founded in 2021 and headquartered in the United States, Atomic AI is characterized by its proficient blend of scientists and engineers, whose interdisciplinary expertise is a pivotal element of its success. The company's potential and innovation prowess were endorsed by a Series A investment on 29 August 2023, led by Modi Ventures. Atomic AI's progress in the biotech sector makes it a promising venture in both technological advancement and pharmaceutical solutions.